Aarhus University Seal / Aarhus Universitets segl

Kirsten Bouchelouche

Advances in prostate-specific membrane antigen PET of prostate cancer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

Advances in prostate-specific membrane antigen PET of prostate cancer. / Bouchelouche, Kirsten; Choyke, Peter L.

I: Current Opinion in Oncology, Bind 30, Nr. 3, 05.2018, s. 189-196.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bouchelouche, Kirsten ; Choyke, Peter L. / Advances in prostate-specific membrane antigen PET of prostate cancer. I: Current Opinion in Oncology. 2018 ; Bind 30, Nr. 3. s. 189-196.

Bibtex

@article{3bf33ef0b52c4da09494dfa0a221455b,
title = "Advances in prostate-specific membrane antigen PET of prostate cancer",
abstract = "Purpose of review In recent years, a large number of reports have been published on prostate-specific membrane antigen (PSMA)/PET in prostate cancer (PCA). This review highlights advances in PSMA PET in PCA during the past year. Recent findings PSMA PET/computed tomography (CT) is useful in detection of biochemical recurrence, especially at low prostate-specific antigen (PSA) values. The detection rate of PSMA PET is influenced by PSA level. For primary PCA, PSMA PET/CT shows promise for tumour localization in the prostate, especially in combination with multiparametric MRI (mpMRI). For primary staging, PSMA PET/CT can be used in intermediate and high-risk PCA. Intraoperative PSMA radioligand guidance seems promising for detection of malignant lymph nodes. While the use of PSMA PET/MRI in primary localized disease is limited to high and intermediate-risk patients and localized staging, in the recurrence setting, PET/MRI can be particularly helpful when the lesions are subtle. PSMA PET/CT is superior to choline PET/CT and other conventional imaging modalities. Summary Molecular imaging with PSMA PET continues to pave the way for personalized medicine in PCA. However, large prospective clinical studies are still needed to fully evaluate the role of PSMA PET/CT and PET/MRI in the clinical workflow of PCA.",
keywords = "personalized medicine, PET/CT, PET/MRI, prostate cancer, prostate-specific membrane antigen, PSMA",
author = "Kirsten Bouchelouche and Choyke, {Peter L.}",
year = "2018",
month = may,
doi = "10.1097/CCO.0000000000000439",
language = "English",
volume = "30",
pages = "189--196",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "3",

}

RIS

TY - JOUR

T1 - Advances in prostate-specific membrane antigen PET of prostate cancer

AU - Bouchelouche, Kirsten

AU - Choyke, Peter L.

PY - 2018/5

Y1 - 2018/5

N2 - Purpose of review In recent years, a large number of reports have been published on prostate-specific membrane antigen (PSMA)/PET in prostate cancer (PCA). This review highlights advances in PSMA PET in PCA during the past year. Recent findings PSMA PET/computed tomography (CT) is useful in detection of biochemical recurrence, especially at low prostate-specific antigen (PSA) values. The detection rate of PSMA PET is influenced by PSA level. For primary PCA, PSMA PET/CT shows promise for tumour localization in the prostate, especially in combination with multiparametric MRI (mpMRI). For primary staging, PSMA PET/CT can be used in intermediate and high-risk PCA. Intraoperative PSMA radioligand guidance seems promising for detection of malignant lymph nodes. While the use of PSMA PET/MRI in primary localized disease is limited to high and intermediate-risk patients and localized staging, in the recurrence setting, PET/MRI can be particularly helpful when the lesions are subtle. PSMA PET/CT is superior to choline PET/CT and other conventional imaging modalities. Summary Molecular imaging with PSMA PET continues to pave the way for personalized medicine in PCA. However, large prospective clinical studies are still needed to fully evaluate the role of PSMA PET/CT and PET/MRI in the clinical workflow of PCA.

AB - Purpose of review In recent years, a large number of reports have been published on prostate-specific membrane antigen (PSMA)/PET in prostate cancer (PCA). This review highlights advances in PSMA PET in PCA during the past year. Recent findings PSMA PET/computed tomography (CT) is useful in detection of biochemical recurrence, especially at low prostate-specific antigen (PSA) values. The detection rate of PSMA PET is influenced by PSA level. For primary PCA, PSMA PET/CT shows promise for tumour localization in the prostate, especially in combination with multiparametric MRI (mpMRI). For primary staging, PSMA PET/CT can be used in intermediate and high-risk PCA. Intraoperative PSMA radioligand guidance seems promising for detection of malignant lymph nodes. While the use of PSMA PET/MRI in primary localized disease is limited to high and intermediate-risk patients and localized staging, in the recurrence setting, PET/MRI can be particularly helpful when the lesions are subtle. PSMA PET/CT is superior to choline PET/CT and other conventional imaging modalities. Summary Molecular imaging with PSMA PET continues to pave the way for personalized medicine in PCA. However, large prospective clinical studies are still needed to fully evaluate the role of PSMA PET/CT and PET/MRI in the clinical workflow of PCA.

KW - personalized medicine

KW - PET/CT

KW - PET/MRI

KW - prostate cancer

KW - prostate-specific membrane antigen

KW - PSMA

UR - http://www.scopus.com/inward/record.url?scp=85045519261&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000439

DO - 10.1097/CCO.0000000000000439

M3 - Review

C2 - 29465429

AN - SCOPUS:85045519261

VL - 30

SP - 189

EP - 196

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 3

ER -